Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
USRE41288E1 · kind E1 · reissue
16Cited by
9References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2004 |
| Grant date | Apr 27, 2010 |
| Priority date | — |
| Expiry date | Aug 6, 2024 |
Classification
- Technology area (CPC —)General
Abstract
It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.